Aspirin Marketing MDL Bears Down on Bayer

Law360, New York (July 13, 2009, 12:00 AM EDT) -- Consumers accusing Bayer Healthcare LLC of promoting its aspirin products without regulatory approval have banded together in multidistrict litigation, filing a master complaint alleging the pharmaceutical giant illegally marketed its combination aspirins as a way to fend off heart and bone disease.

The master complaint, lodged Monday in the U.S. District Court for the Eastern District of New York, claims Bayer has profited unlawfully and endangered consumers by selling two combination aspirin products as dietary supplements without the necessary regulatory approval.

Bayer markets its Bayer Aspirin...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.